Gosset Ownership
Private
Employees
~49
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Innogene Kalbiotech General Information
Innogene Kalbiotech has successfully commercialized biosimilars and novel diagnostics—most notably the Mammaprint breast cancer recurrence assay—and continues to run clinical trials for additional biopharmaceuticals. The company has a proven track record of bringing products from development through regulatory approval to market across Asia.
Contact Information
Primary Industry
Biotech
Corporate Office
Singapore,
Singapore
Singapore
Drug Pipeline
nimotuzumab
CommercialKey Partnerships
Collaborates with companies for clinical development and distribution; part of the broader Kalbe Group network which includes PT Kalbe Genexine Biologics, Also works with diagnostic partners such as those involved in Mammaprint
Innogene Kalbiotech Funding
No funding data available
To view Innogene Kalbiotech's complete valuation and funding history, request access »